Skip to main content

Rossari Biotech debuts at Rs 670 with 58% premium over IPO price

The listing premium was much higher than the grey market premium (of around Rs 160-180 per share) as well as analysts' expectations of Rs 130-175 per share.

The Mumbai-based specialty chemical maker Rossari Biotech started the first trading day with a whopping 57.65 percent premium over its IPO price on July 23.

The stock opened at Rs 670 on the BSE, up by Rs 245 over the issue price of Rs 425 per share, while on the National Stock Exchange, it debuted at Rs 669.25, a 57.47 percent premium over IPO price.

It was much higher than the grey market premium (of around Rs 160-180 per share) as well as analysts' expectations of Rs 130-175 per share.

At 10:01 hours IST, the stock was trading at Rs 675 on the BSE, up by Rs 250 or 58.82 percent over issue price with a volume of 3.83 lakh shares.

The exchange has fixed a 20 percent upper and lower circuit limit at Rs 804 and Rs 536 respectively, over its opening price of Rs 670.

On the National Stock Exchange, the share price traded at Rs 676.75, up by Rs 251.75 or 59.24 percent over IPO price, with volumes of 40,88,564 equity shares.

The Rs 496-crore initial public offering of Rossari Biotech had seen a hefty subscription of 79.37 times during July 13-15.

The public issue consisted a fresh issue of Rs 50 crore and offer for sale of 1.05 crore shares by promoters Edward Menezes and Sunil Chari.

Promoters and promoter group's shareholding in the company reduced to 72.69 percent post issue, from 95.06 percent earlier.


The company will utilise fresh issue proceeds for repayment/prepayment of certain indebtedness (including accrued interest) and funding working capital requirements, while it will not receive any funds from offer for sale.

Rossari manufactures majority of its products in-house from its Silvassa manufacturing facility which has an installed capacity of 1,20,000 MTPA. Now the company is currently setting up another manufacturing facility at Dahej in Gujarat with a proposed installed capacity of 1,32,500 MTPA which will enjoy proximity to the deep water, multi-cargo port of Dahej. The proposed state-of-the-art facility will be fully operational by March 2021.

Manufacturing of disinfectants & sanitizers as part of the Home, Personal Care & Performance Chemicals led the company's products to get categorized under essential goods, thus its manufacturing facility at Silvassa was not shut down during COVID-19 lockdown period.

Previously, company's business was much dependent on the textile space (nearly 71 percent revenue came from textile in FY18 which reduced to 44 percent in FY20), but steadily company has brought down the revenue share and simultaneously the revenue share of Home & Personal care division has increased and current it accounts nearly 47 percent of FY20 revenue, which turns a big positive for Rossari Biotech, said Ashika Stock Broking.

Source - Moneycontrol

 


Labels:

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

  Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...
Post a Comment
Read more